English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduNanostics is expanding its ClarityDX Prostate clinical validation study into the US by opening the Florida-based Century Clinical Research Inc. recruitment site; significantly accelerating the study timeline and increasing patient cohort diversity.
Tag: prostate cancer
Clues from DNA could help predict growth of prostate cancer
Researchers from the UCLA Jonsson Comprehensive Cancer Center and other institutions in the U.S., Canada, the United Kingdom and Singapore, have identified 1,178 biomarkers in men’s genomes — the complete set of genetic material inherited from one’s parents — that predict how an individual person’s prostate cancer will grow.
The finding suggests that predicting how a person’s cancer will evolve may lie in their inherited DNA.
Microbiome provides new clues to determining development of colon cancer
A team from the George Washington University published research in the journal Gastroenterology, which found a connection between bacterial species living in the microbiome and development of colon cancer
SKCC to host 2019 Philadelphia Prostate Cancer Consensus Conference
An international panel of experts will identify the best approaches to implement genetic testing for men with prostate cancer
Study: Biomarker in Urine May Offer Non-invasive Detection of Prostate Cancer
A research study published in the journal Neoplasia and led by principal investigator Nallasivam Palanisamy, Ph.D., associate scientist in the Vattikuti Urology Institute at Henry Ford Health System, has identified a novel prostate cancer gene fusion involving the KLK4 protein coding gene and KLKP1 pseudogene. This unique biomarker can be detected in the urine samples of patients with prostate cancer, offering a non-invasive means of detection.
Study: Biomarker in urine may offer noninvasive detection of prostate cancer
DETROIT – A research study published in the journal Neoplasia and led by principal investigator Nallasivam Palanisamy, Ph.D. , associate scientist in the Vattikuti Urology Institute at Henry Ford Health System, has identified a novel prostate cancer gene fusion involving…
Cloning to fight esophageal cancer
Recreating the steps to malignancy leads to faster drug discovery
Targeted therapy slows progression of advanced prostate cancer
ESMO 2019 Congress, Sept. 27 — Oct. 1, Barcelona, Spain
First prostate cancer therapy to target genes delays cancer progression
Genetic-based treatment nearly doubles time without disease progression in metastatic prostate cancer
ESMO 2019: Breast and ovarian cancer drug outperforms targeted hormone therapy in some men
A drug used for breast and ovarian cancer is more effective than modern targeted hormone treatments at slowing progression and improving survival in some men with advanced prostate cancer, phase III clinical trial findings reveal. The PROfound trial compared the…
Modern chemo better than second targeted hormone therapy against resistant prostate cancer
A modern chemotherapy drug is more effective for men with advanced prostate cancer than a second targeted hormone therapy in patients who have stopped responding to treatment, a major clinical trial shows. Men who had stopped responding to either abiraterone…
New blood test capable of detecting multiple types of cancer
In study, test proved able to detect and localize more than 20 types of cancer with a high degree of accuracy; Test detected methylation patterns associated with cancer in free-floating DNA in blood
Men with prostate cancer can be spared radiotherapy after surgery
ESMO 2019 Congress, Sept. 27 – Oct. 1, Barcelona, Spain
Men can be spared radiotherapy after surgery
Largest ever trial in postoperative prostate cancer patients confirms that men can be spared radiotherapy after surgery
Long-term hormone tx increases mortality risk for men with low PSA after prostate surgery
Analysis finds PSA levels predict which men with recurrent prostate cancer will be harmed by adding long-term hormone therapy to radiation
Trial finds high-dose radiation effective for men whose prostate cancer has spread
Phase II, randomized trial data show targeted radiation sparks immune system response similar to vaccination
Semen miRNAs could be non-invasive biomarkers for prostate cancer
Researchers of the Human Molecular Genetics group at the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Sara Larriba, in collaboration with Dr. Francesc Vigués and Dr. Manel Castells of the Urology Service of Bellvitge University Hospital (HUB), show the…
Fathering children by assisted reproduction linked to increased risk of prostate cancer
Early screening and long term monitoring should be considered for these men, say researchers
GW Cancer Center Researchers Find Potential Therapeutic Target for Prostate Cancers with PTEN Mutation
PTEN, a tumor suppressor gene mutated in about 20% of prostate cancers, relies on another gene, ARID4B, to function. These findings were published by George Washington University Cancer Center researchers in Nature Communications.
Study finds potential therapeutic target for prostate cancers with PTEN mutation
Researchers from the George Washington University published their findings on the connection between the PTEN gene and the ARID4B gene in Nature Communications
Empowering cancer patients to shift their mindsets could improve care, researchers argue
A diagnosis of cancer can cause significant emotional burden for patients and their families. The turmoil may persist throughout treatment and even years into survivorship. As a result, depression and anxiety are two to three times more common in cancer…
Urologic Cancer Expert Brings Latest Science to NYU Langone Hospital–Brooklyn
Mohit Gupta, MD, has been appointed director of urologic oncology and brings the latest surgical techniques in the treatment of prostate and urinary cancers to NYU Langone Hospital–Brooklyn.
Urologic Cancer Expert Brings Latest Science to NYU Langone Hospital–Brooklyn
Mohit Gupta, MD, has been appointed director of urologic oncology and brings the latest surgical techniques in the treatment of prostate and urinary cancers to NYU Langone Hospital–Brooklyn.
Targeted radiotherapy technique could cut treatment time from two months to two weeks
Advanced radiotherapy technology could safely deliver curative treatment for some prostate cancer patients in just one or two weeks, according to new research published today.
Pre-salvage RT PSA predictive of hormone therapy benefit with salvage RT for recurrent prostate cancer
Pre-salvage RT PSA is predictive of hormone therapy benefit with salvage RT for men with recurrent prostate cancer on NRG oncology trial
New SU2C teams accelerate clinical trials for difficult breast & prostate cancers
LOS ANGELES – Stand Up To Cancer (SU2C) is launching teams of experts to lead innovative attacks on two types of cancer that have defied conventional treatment: triple-negative breast cancer (TNBC) in women and metastatic prostate cancer in men. The…
Search tightens for genes driving prostate cancer
The National Cancer Institute (NCI) is set up to fund individual projects in fields like genomics, computational biology, and pathology. Now researchers at University of Colorado Cancer Center are taking advantage of an innovative new program in cancer systems biology…
New blood test for prostate cancer is highly-accurate and avoids invasive biopsies
A new and simple blood test has been found to efficiently and accurately detect the presence of aggressive prostate cancer, according to research by Queen Mary University of London. In combination with the current prostate specific antigen (PSA) test, the…
Eating mushrooms may help lower prostate cancer risk
A new study published in the International Journal of Cancer found an inverse relationship between mushroom consumption and the development of prostate cancer among middle-aged and elderly Japanese men, suggesting that regular mushroom intake might help to prevent prostate cancer.…
Obesity and psychosocial well-being among patients with cancer
In a study published in Psycho-Oncology , excess weight was linked with poorer psychosocial health among older adults diagnosed with breast cancer or prostate cancer. The association was not seen in older patients with colon cancer, however. In the study…
UTA scientist explores using nanoparticles to reduce size of deep-seated tumors
Another collaborative project from a nanoparticles expert at The University of Texas at Arlington has yielded promising results in the search for more effective, targeted cancer treatments. Wei Chen, in collaboration with colleagues from the University of Rhode Island and…
LSU Health New Orleans awarded $13.6 million for expanded cancer clinical trials network
New Orleans, LA – LSU Health New Orleans has been awarded a $13.6 million grant by the National Cancer Institute to expand its successful statewide clinical trials network with a special emphasis on minority and underserved cancer patients. Principal Investigator…
Blocking specific protein could provide new treatment for deadly form of prostate cancer
Study provides rationale for clinical trial evaluating CDK7 inhibitors
A dual imaging approach may improve diagnosis and monitoring of prostate cancer
A new platform that combines two established imaging methods can peer into both the structure and molecular makeup of the prostate in men with prostate cancer. The technology is more sensitive and comprehensive compared to current “gold standard” methods, indicating…
Gold nanoparticles shown to be safe and effective treatment for prostate cancer
Biocompatible gold nanoparticles designed to convert near-infrared light to heat have been shown to safely and effectively ablate low- to intermediate-grade tumors within the prostate, according to a study conducted at the Icahn School of Medicine and published in the…
Gold nanoparticles shown to be safe and effective treatment for prostate cancer
Biocompatible gold nanoparticles designed to convert near-infrared light to heat have been shown to safely and effectively ablate low- to intermediate-grade tumors within the prostate, according to a study conducted at the Icahn School of Medicine and published in the…
Quest for new cancer treatment crosses milestone
Therapy invented at Rice University excels in pilot clinical trials
SOFIE And University Clinic Heidelberg Sign License Agreement For Theranostics That Target Cancer Associated Fibroblasts
LOS ANGELES and HEIDELBERG, Germany, June 21, 2019 /PRNewswire/ — SOFIE Inc. (SOFIE), a Theranostics company, is pleased to announce an exclusive global license with University Clinic Heidelberg (UKHD) for a class of molecular targeted diagnostics and radiotherapeutics (“theranostics”) that are…